Labcorp has announced that the FDA has granted approval for its nAbCyte Anti-AAVRh74var HB-FE Assay. This new protocol is created to function as a companion diagnostic in order to assess a patient's eligibility for BEQVEZ therapy. BEQVEZ is a recently FDA-approved gene therapy designed by Pfizer to treat hemophilia B. The results of the nAbCyte test will be recorded simply as negative or positive. A negative result means a patient who has moderate to severe hemophilia B can be considered for the BEQVEZ treatment.
Pfizer's Head of U.S. Specialty Care Medical Affairs, Sonal Bhatia, stated, "This companion diagnostic is a crucial instrument for determining patients who may be suitable for gene therapy, as the treatment strategy progresses with the introduction of gene therapies like BEQVEZ."
To keep updated with more health-related news like this, please visit rttnews.com.
